FDA allows Curis to resume testing cancer drug

Send a link to a friend  Share

[March 31, 2014]  (Reuters) Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.

The company's shares jumped about 22 percent to $3.35 in trading before the bell.

Enrolment for the study was halted after the death of a patient with advanced breast cancer, who experienced acute liver failure about a month after the drug, codenamed CUDC-427, was discontinued.

The trial began in the third quarter of 2013 in patients with advanced solid tumors or lymphomas.

Curis said it planned to continue testing the drug  including in combination with chemotherapy drug, capecitabine  in patients of a type of advanced breast cancer.

The Lexington, Massachusetts-based company's shares closed at $2.75 on the Nasdaq on Friday.

(Reporting by Natalie Grover in Bangalore; editing by Kirti Pandey)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top